

11<sup>th</sup> February, 2025

To,  
The Manager - Corporate Relationship Dept.  
BSE Limited  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001

To,  
The Manager - Corporate Compliance  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot No.C-1,  
G Block,BKC, Bandra (E),  
Mumbai 400 051

**Scrip Code: BSE - 524500**

**Scrip Code: NSE - KILITCH**

**Sub: Integrated Filing (Financials) for the quarter ended 31<sup>st</sup> December, 2024**

Dear Sir,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No.20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 02, 2025, we are submitting herewith the Integrated Filing (Financials) for the quarter ended 31<sup>st</sup> December, 2024.

The above announcement is also being made available on the website of the Company at [www.kilitch.com](http://www.kilitch.com)

Request you to kindly take note of the same and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

**Mukund Mehta**  
**Managing Director**  
**DIN: 00147876**





**KILITCH DRUGS (INDIA) LIMITED**

**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024**

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

		Three Months Ended			Nine Months Ended		Year Ended
		31/12/2024	30/09/2024	31/12/2023	31/12/2024	31/12/2023	31/03/2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income</b>						
	Net Sales/ Income from operations	4,651.32	4,534.84	2,976.50	12,528.33	9,246.34	13,159.90
	Other Income	237.00	580.90	339.50	1,139.06	529.22	618.85
	<b>Total Income</b>	<b>4,888.32</b>	<b>5,115.74</b>	<b>3,316.00</b>	<b>13,667.39</b>	<b>9,775.56</b>	<b>13,778.75</b>
2	<b>Expenses</b>						
	Cost of Materials Consumed	2,449.58	2,294.85	1,490.96	6,606.30	4,392.51	6,633.24
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	22.48	16.54	27.27	28.03	22.20	(11.61)
	Employee Benefit Expenses	273.02	249.32	203.38	744.78	600.54	791.35
	Finance Cost	49.42	42.04	53.47	140.46	146.33	190.81
	Depreciation and Amortisation Expenses	47.49	40.24	29.85	122.65	83.39	124.42
	Export Product Registration/Commission	416.19	560.90	295.72	1,350.88	830.81	1,392.62
	Other Expenses	678.23	853.81	557.31	2,105.16	1,890.26	2,322.61
	<b>Total Expenses</b>	<b>3,936.41</b>	<b>4,057.70</b>	<b>2,657.96</b>	<b>11,098.26</b>	<b>7,966.04</b>	<b>11,443.44</b>
3	<b>Profit / (Loss) before Exceptional items (1-2)</b>	<b>951.91</b>	<b>1,058.04</b>	<b>658.04</b>	<b>2,569.13</b>	<b>1,809.52</b>	<b>2,335.31</b>
4	Exceptional Items	-	-	-	-	-	-
5	<b>Profit / (Loss) from ordinary activities before tax (3+4)</b>	<b>951.91</b>	<b>1,058.04</b>	<b>658.04</b>	<b>2,569.13</b>	<b>1,809.52</b>	<b>2,335.31</b>
6	Less: Tax Expenses:-						
	Current Tax	286.55	216.09	130.15	629.14	505.00	636.50
	Deferred Tax	(22.94)	(42.64)	(22.07)	(38.31)	(88.65)	(58.57)
7	<b>Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)</b>	<b>688.30</b>	<b>884.59</b>	<b>549.96</b>	<b>1,978.30</b>	<b>1,393.17</b>	<b>1,757.38</b>
8	Other Comprehensive Income (after tax)	(123.10)	(13.19)	109.79	(20.28)	452.66	556.13
9	<b>Total Comprehensive Income (after taxes) (7+8)</b>	<b>565.20</b>	<b>871.40</b>	<b>659.75</b>	<b>1,958.02</b>	<b>1,845.83</b>	<b>2,313.51</b>
10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,608.23	1,608.23	1,608.23	1,608.23	1,608.23	1,608.23
11	Other Equity						20,684.13
12	<b>Earning per share (not annualised)</b>						
	(a) Basic	4.28	5.50	3.48	12.30	8.77	11.03
	(b) Diluted	4.28	5.50	3.48	12.30	8.77	11.03

**Notes:**

- The above Unaudited Standalone Financial Results of the Company for the quarter and nine months ended 31st December, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11th February, 2025.  
The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The figures for the corresponding previous periods/year have been regrouped/rearranged, wherever necessary, to make them comparable with the current period.

For and on behalf of the Board of Directors

Place : Mumbai  
Dated: 11th February, 2025

Mukund Mehta  
Director  
DIN:- 00147876



**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,

**The Board of Directors of  
Kilitch Drugs (India) Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Kilitch Drugs (India) Limited** (the 'Company') for the quarter and nine months ended 31st December, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended (the "Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules thereafter and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The standalone financial results of the Company for the quarter and nine months ended 31st December, 2023 were reviewed by the predecessor auditor, M/s. Suryaprakash Maurya & Co, who have expressed an unmodified opinion on those financial results.



5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For C sharat & Associates**  
**Chartered Accountants**  
**FRN: 128593W**

CHINTAN  
SHARATCHA  
NDRA SHAH

Digitally signed by  
CHINTAN  
SHARATCHANDRA SHAH  
Date: 2025.02.11 17:33:20  
+05'30'



**Chintan Sharatchandra Shah**  
**Partner**  
**Mem. No: 127551**  
**UDIN NO: 25127551BMIIEN3495**  
**Date: 11/02/2025**  
**Place: Mumbai**

**KILITCH DRUGS (INDIA) LIMITED**  
**CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024**


Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane- 400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	CONSOLIDATED					
		Three Months Ended			Nine Month Ended		Year Ended
		31/12/2024	30/09/2024	31/12/2023	31/12/2024	31/12/2023	31/03/2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income</b>						
	Net Sales/Income from Operations	5,616.61	4,747.49	3,179.45	13,709.26	10,955.37	15,437.25
	Other Income	172.52	516.42	295.61	946.31	400.77	447.89
	<b>Total Income</b>	<b>5,789.13</b>	<b>5,263.91</b>	<b>3,475.06</b>	<b>14,655.57</b>	<b>11,356.14</b>	<b>15,885.14</b>
2	<b>Expenses</b>						
	Cost of Materials Consumed	3,253.57	2,442.56	1,671.60	7,560.24	5,398.37	7,907.82
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	22.48	16.54	27.27	28.03	22.20	(11.61)
	Employee Benefit Expenses	314.19	259.23	250.68	844.31	764.17	1,001.31
	Finance Cost	140.30	30.55	159.87	344.00	460.71	592.94
	Depreciation and Amortisation Expenses	80.74	60.50	81.48	226.35	242.05	334.96
	Export Product Registration/Commission	416.28	561.07	296.11	1,351.55	833.46	1,395.25
	Other expenses	736.49	858.82	705.80	2,276.36	2,229.42	2,729.02
	<b>Total Expenses</b>	<b>4,964.05</b>	<b>4,229.27</b>	<b>3,192.81</b>	<b>12,630.84</b>	<b>9,950.38</b>	<b>13,949.69</b>
3	<b>Profit before Exceptional items (1-2)</b>	<b>825.08</b>	<b>1,034.64</b>	<b>282.25</b>	<b>2,024.73</b>	<b>1,405.76</b>	<b>1,935.45</b>
4	Exceptional Items	-	-	-	-	-	-
5	<b>Profit from ordinary activities before tax (3+4)</b>	<b>825.08</b>	<b>1,034.64</b>	<b>282.25</b>	<b>2,024.73</b>	<b>1,405.76</b>	<b>1,935.45</b>
6	Less : Tax Expenses						
	Current Income Tax	286.55	216.09	130.15	629.14	505.00	636.50
	Deferred Tax	(22.94)	(42.63)	(22.06)	(38.25)	(88.69)	(58.57)
7	<b>Profit after tax for the period from continuing operations (5-6)</b>	<b>561.47</b>	<b>861.18</b>	<b>174.16</b>	<b>1,433.84</b>	<b>989.45</b>	<b>1,357.52</b>
	Add/(Less): Share in Profits /(Loss) of Associates	-	-	-	-	-	-
	Net Profit/(Loss) After Tax & Share in Profits /(Loss) of						
8	Associates	561.47	861.18	174.16	1,433.84	989.45	1,357.52
9	Other Comprehensive Income (after Tax)	(123.10)	(13.19)	109.79	(20.28)	452.65	556.13
10	<b>Total Comprehensive Income (after taxes) (8+9)</b>	<b>438.37</b>	<b>847.99</b>	<b>283.95</b>	<b>1,413.56</b>	<b>1,442.10</b>	<b>1,913.65</b>



<b>11</b>	<b>Net Profit / (Loss) attributable to</b>						
	a) Owner of the Company	596.09	861.70	290.93	1,591.81	1,100.72	1,460.14
	b) Non Controlling interest	(34.62)	(0.52)	(116.77)	(157.97)	(111.27)	(102.62)
<b>12</b>	<b>Other Comprehensive Income attributable to</b>						
	a) Owner of the Company	(123.10)	(13.19)	109.79	(20.28)	452.65	556.13
	b) Non Controlling interest	-	-	-	-	-	-
<b>13</b>	<b>Total Income attributable to</b>						
	a) Owner of the Company	472.99	848.51	400.72	1,571.53	1,553.37	2,016.27
	b) Non Controlling interest	(34.62)	(0.52)	(116.77)	(157.97)	(111.27)	(102.62)
<b>14</b>	<b>Paid-Up equity share capital (Face Value Rs. 10 per share)</b>	<b>1,608.23</b>	<b>1,608.23</b>	<b>1,608.23</b>	<b>1,608.23</b>	<b>1,608.23</b>	<b>1,608.23</b>
<b>15</b>	<b>Other Equity</b>						<b>16,020.89</b>
<b>16</b>	<b>Earning per share (not annualised)</b>						
	(a) Basic	3.71	5.36	1.85	9.90	6.93	9.17
	(b) Diluted	3.71	5.36	1.85	9.90	6.93	9.17

**Notes:**

1. The above Unaudited Consolidated Financial Results of the Company for the quarter and nine months ended 31st December, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11th February, 2025.
2. The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
3. The figures for the corresponding previous periods/year have been reclassified/rearranged, wherever necessary, to make them comparable with the current periods.

For and on behalf of the Board of Directors

Mukund P. Mehta

Director

DIN:- 00147876



Place: Mumbai  
Date: 11th February, 2025



**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Kilitch Drugs (India) Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,

**The Board of Directors of  
Kilitch Drugs (India) Limited**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Kilitch Drugs (India) Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended 31st December, 2024 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.



4. The Statement includes the results of entities as given below:

**List of Subsidiaries:**

1. Monarchy Healthserve Private Limited
2. Kilitch Estro Biotech PLC – Foreign Subsidiary

The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects, total revenues of Rs.966.11 Lakhs and Rs.1,183.32 Lakhs for quarter and nine months ended 31st December, 2024 respectively, total Net Profit/(Loss) after tax of Rs. (103.90) Lakhs and Rs. (478.70) Lakhs for quarter and nine months ended 31st December, 2024 respectively, total comprehensive income/(loss) of Rs. (103.90) Lakhs and Rs.(478.70) Lakhs for the quarter and nine months ended 31st December, 2024 as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management.

5. (a) We did not review the interim financial results and other financial information in respect of one subsidiary whose interim financial results/information reflects, total revenues of Rs. Nil and Rs. Nil for quarter and nine months ended 31st December, 2024 respectively, total Net Profit/(Loss) after tax of Rs. (21.93) Lakhs and Rs. (65.74) Lakhs for quarter and nine months ended 31st December, 2024 respectively, total comprehensive income/(loss) of Rs. (21.93) Lakhs and Rs.(65.74)Lakhs for the quarter and nine months ended 31st December, 2024. These interim financial results and other financial information have been reviewed by other auditors, whose reports have been furnished to us by the management of the Company and our conclusion in so far as it relates to the affairs of such subsidiary is based solely on the report of other auditors.

(b)The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects ,total assets of Rs. 4,774.13 Lakhs, total revenues of Rs. 214.00 Lakhs and Rs. 217.21 Lakhs, total net profit/(loss) after tax of Rs.(1.56) Lakhs and Rs. (373.80) Lakhs and total comprehensive income/(loss) of Rs. (1.56) Lakhs and Rs. (373.80) Lakhs for the quarter ended 30th September, 2024 and for the period from 1st April, 2024 to 30th September, 2024, respectively and net cash inflow of Rs. 47.88 Lakhs for the period from 1st April, 2024 to 30th September, 2024 as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management.

Our conclusion on the Statement is not modified in respect of the above matter.

6. The consolidated financial results of the Company for the quarter and nine months ended 31st December, 2023 were reviewed by the predecessor auditor, M/s. Suryaprakash Maurya & Co, who have expressed an unmodified opinion on those financial results.



7. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statements referred in paragraph 5 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For C sharat & Associates**  
**Chartered Accountants**  
**FRN: 128593W**

CHINTAN  
SHARATCHAN  
DRA SHAH

Digitally signed by  
CHINTAN  
SHARATCHANDRA SHAH  
Date: 2025.02.11 17:23:51  
+05'30'



**Chintan Sharatchandra Shah**  
**Partner**

**Mem. No: 127551**  
**UDIN NO: 25127551BMIIEM1987**  
**Date: 11/02/2025**  
**Place: Mumbai**



**B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.**

**Not Applicable**

**C. DISCLOSURE OF OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES**

**There is No default, hence not Applicable**

**D. DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for halfyearly filings i.e., 2nd and 4th quarter)**

**Not Applicable**

**E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter)**

**Not Applicable**

